Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.

Singer-actor IU donated 300 million won ($200,160) to mark her birthday on Saturday, her agency Edam Entertainment said. The ...

While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...

With Eli Lilly’s diabetes and obesity treatment Mounjaro overtaking MSD’s cancer therapy Keytruda as the world’s top-selling ...

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") is pleased to announce results of voting at its annual and special meeting of unitholders held on May 15, 2026. All of the nominees ...

Phase 1 monotherapy data in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) on track for mid-year 2026; update to include analyses focused on patients treated at or below a ...

TuHURA Biosciences, Inc. ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results ...

Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...

A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.

Pharma stocks are gaining momentum as obesity drugs, oncology therapies and biotech innovation boost investor optimism.

Citius Oncology, Inc. ("Citius Oncology" or the "Company") , the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today reported financial results for the fiscal second ...